Key facts
- This page summarizes Hubert C. Chen's Form 4 filing for Forte Biosciences, Inc. (FBRX).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jan 2024, 16:04.
Hubert C. Chen - 01 Jan 2024 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)
- Reporting relationship
- President and Chief Scientific Officer
- Issuer ticker
- FBRX
- Reported as of
- 01 Jan 2024
- Net transaction value
- -$2,525
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2024, 16:04:40 UTC
- Prior SEC filing
- 03 Oct 2023
- Next SEC filing
- 03 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Hubert C. Chen filed Form 4 for Forte Biosciences, Inc. (FBRX) on 03 Jan 2024.
Change
- Previous filing in this sequence was filed on 03 Oct 2023.
- Current net transaction value: -$2,525.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FBRX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +7,500
- Change %
- +8.4%
- Price
- $0.000000
- Shares after
- 96,478
- Date
- 01 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
FBRX
transaction
Common Stock
Tax liability
- Transaction value
- $2,525
- Shares
- -3,073
- Change %
- -3.2%
- Price
- $0.8217
- Shares after
- 93,405
- Date
- 01 Jan 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FBRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -7,500
- Change %
- -7.7%
- Price
- $0.000000
- Shares after
- 90,000
- Date
- 01 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,500
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.
Footnote F2
On January 1, 2024, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on December 29, 2023 was the settlement price used to calculate the shares withheld.
Footnote F3
Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.
SEC remarks
President and Chief Scientific Officer